These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 28933670)

  • 1. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
    Wason J; Marshall A; Dunn J; Stein RC; Stallard N
    Br J Cancer; 2014 Apr; 110(8):1950-7. PubMed ID: 24667651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of the interim analysis in adaptive enrichment designs.
    Benner L; Kieser M
    J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial designs for predictive biomarker validation: one size does not fit all.
    Mandrekar SJ; Sargent DJ
    J Biopharm Stat; 2009; 19(3):530-42. PubMed ID: 19384694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II cancer clinical trials for biomarker-guided treatments.
    Jung SH
    J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision medicine needs randomized clinical trials.
    Saad ED; Paoletti X; Burzykowski T; Buyse M
    Nat Rev Clin Oncol; 2017 May; 14(5):317-323. PubMed ID: 28169302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker enrichment strategies: matching trial design to biomarker credentials.
    Freidlin B; Korn EL
    Nat Rev Clin Oncol; 2014 Feb; 11(2):81-90. PubMed ID: 24281059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment design with patient population augmentation.
    Yang B; Zhou Y; Zhang L; Cui L
    Contemp Clin Trials; 2015 May; 42():60-7. PubMed ID: 25746817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.